Agoracom Blog Home

Posts Tagged ‘biopharma’

Quantum BioPharma (Formerly FSD Pharma) Sues CIBC, RBC & Others For $700 Million Alleging Spoofing/Short Selling Stock Manipulation

Posted by Brittany McNabb at 5:21 PM on Tuesday, November 19th, 2024

In a bold move to safeguard its interests and fight back against market manipulation, Quantum BioPharma (Formerly FSD Pharma)has filed a $700 million lawsuit against CIBC, RBC & Others. The lawsuit alleges that the banks engaged in the controversial practice of “spoofing,” which involves manipulating stock prices by placing fake buy and sell orders to create a false illusion of market demand or supply. According to Quantum BioPharma, this tactic has been used to artificially depress its stock price, potentially causing substantial harm to its investors and undermining the company’s growth prospects.

The Allegations: A Market Manipulation Scheme

Zeeshan Saeed, CEO of Quantum BioPharma, discussed the shock of discovering that the company’s stock had been targeted by a manipulation scheme. He explained that spoofing, a practice where orders are placed and canceled in fractions of a second, can have a profound impact on market prices. These orders are meant to deceive other investors into believing that there is either a shortage of supply or an excess of demand, thus influencing market behavior without any intention to execute the orders. While the practice can be difficult to track due to the speed and subtlety of the actions involved, its effects on stock prices can be devastating.

The suit alleges that CIBC, RBC & others used this technique to artificially suppress Quantum BioPharma’s stock price, potentially wiping out substantial investor value. The company claims that this market manipulation has not only impacted its share price but has also hindered its ability to raise capital, secure financing, and pursue its growth strategies.

A Systemic Issue Impacting Micro-Cap Companies

The conversation extended to the broader implications of stock manipulation, particularly for micro-cap and nano-cap companies that are especially vulnerable to such tactics. Jason Sawyer, Head of Finance and M&A, pointed out that small companies with lower market capitalization and liquidity are often the targets of these manipulations. These tactics are detrimental not only to individual companies but to the entire market ecosystem, particularly in Canada’s venture capital sector. Sawyer emphasized that the loss of trust in the integrity of financial markets—especially within the micro-cap space—has had far-reaching consequences, making it increasingly difficult for companies like Quantum BioPharma to attract investment.

Both Saeed and Sawyer underscored that this lawsuit is not only important for Quantum BioPharma but for many other companies in the sector that may have been victims of similar manipulation. The legal action seeks to address a systemic issue that has been undermining the growth of innovative companies and damaging the confidence of retail investors.

A Legal Strategy with Significant Implications

Quantum BioPharma’s lawsuit, filed in the Southern District of New York, is a strategic step to ensure that the company’s interests are protected and that justice is served. The Southern District is renowned for its experience in handling complex financial cases, making it a favorable jurisdiction for cases of this nature.

The law firm representing Quantum BioPharma is taking the case on a contingency basis, signaling confidence in the strength of the lawsuit. This mirrors past successful cases, such as Erin Brockovich’s legal efforts, and suggests that the firm believes the case has merit without requiring upfront payment. Shareholders of Quantum BioPharma have expressed strong support for the lawsuit, recognizing its potential to restore fairness and the natural order to supply and demand in the company’s market activity, while compensating the company for the immense damage caused.

Additionally, the company is providing a platform for investors who believe they have been harmed by the alleged manipulation, offering them the opportunity to join the legal action and submit claims. This has fostered a sense of unity among shareholders and further strengthens the company’s resolve in its legal battle.

Potential Industry-Wide Impact

This lawsuit has the potential to set a significant precedent for other companies affected by similar forms of market manipulation. Quantum BioPharma has already received inquiries from other firms seeking guidance on how to pursue similar legal actions, highlighting the broader relevance of the case.

While the lawsuit is expected to take time, with motions to dismiss likely to be filed by the banks, the company remains focused on its core business activities. The litigation is seen as a crucial step in protecting the company’s long-term interests and ensuring that its shareholders are treated fairly in the marketplace. Discovery, the phase in which both parties exchange evidence, is expected to begin after motions are resolved, which could take 9 to 15 months.

Commitment to Shareholders and Future Growth

Quantum BioPharma has made it clear that its primary focus remains the ongoing commercialization of its innovative biotech products, including its neuroprotective compound, Lucid-MS. However, the company views the legal action as a secondary but essential part of its strategy to secure a fair and transparent market environment. A successful outcome in the lawsuit could not only recover damages for the company but also provide significant financial support for continued research and development, as well as potential acquisitions.

Furthermore, Quantum BioPharma’s leadership has reaffirmed its commitment to its shareholders. The company’s actions, including the filing of this lawsuit and its ongoing efforts to protect investor value, demonstrate its determination to safeguard the interests of its investors and ensure that the company can continue to thrive despite the challenges it faces.

Conclusion: Fighting for Market Integrity

Quantum BioPharma’s lawsuit is a bold stand against market manipulation and an important step in the broader fight for fairness and transparency in financial markets. By taking legal action against two of Canada’s largest banks, the company is not only seeking justice for itself and its investors but is also sending a message that such manipulative practices will not be tolerated.

As the legal battle unfolds, Quantum BioPharma remains committed to its mission of advancing groundbreaking biotech solutions while ensuring that its shareholders can invest in a company that values integrity, transparency, and accountability. The outcome of this case could have far-reaching implications for the biotech sector, offering a crucial opportunity to restore trust in the venture capital markets and set a positive precedent for other companies facing similar challenges.

Quantum BioPharma Sues CIBC, RBC & Others For $700 Million Alleging Spoofing/Short Selling Stock Manipulation

Posted by Brittany McNabb at 3:18 PM on Monday, November 18th, 2024

Quantum BioPharma (Formerly FSD Pharma) has filed a groundbreaking $700 million lawsuit against major Canadian banks, CIBC and RBC, alleging a scheme of stock price manipulation known as “spoofing.” CEO and Co-Chairman Zeeshan Saeed explains that this isn’t just a shot in the dark—industry experts estimate that damages could exceed $1 billion for $QNTM. 

The company’s legal team, confident in the strength of the case, has agreed to take it on a contingency basis, signaling their belief that this could be a watershed moment for both Quantum BioPharma and the entire small cap sector.

“Our goal is to seek justice for our shareholders and stop manipulative practices that hurt ordinary investors,” Saeed stated, underscoring the severity of the issue.

SPOOFING: A MARKET MANIPULATION TACTIC WITH HIGH STAKES

The crux of the lawsuit revolves around a deceptive trading tactic known as spoofing, where large orders are placed and then canceled to manipulate stock prices. According to Zeeshan, this method has been used by CIBC and other financial institutions to artificially drive down Quantum BioPharma’s share price, resulting in significant losses. This isn’t an isolated issue—similar market manipulation has been flagged by advocacy groups like Save Canadian Mining.

The case has been filed in the U.S. District Court for the Southern District of New York, a jurisdiction known for its expertise in financial offenses. Zeeshan emphasized the importance of this venue, noting that “the judges understand the nuances of these complex financial crimes.”

FIGHTING FOR SHAREHOLDERS

Beyond the financial toll, the impact on shareholder confidence has been severe. Zeeshan spoke candidly about the personal toll this manipulation has taken, including threats to his safety. Yet, he remains steadfast in his commitment to Quantum BioPharma’s future, outlining a strategy that could see the company investing in its pipeline and potentially issuing dividends to shareholders if the lawsuit is successful.

George and Zeeshan both drew comparisons to landmark legal battles like the Erin Brockovich case, illustrating how a small player can take on corporate giants and make a real difference.

If you enjoy David vs Goliath stories, watch or listen to this interview to see how this could transform Quantum BioPharma’s future and potentially end market manipulation in the small cap sector once and for all.

VIDEO – AGORACOM Beyond The Expert Welcomes Venture Capitalist Leigh Hughes To Discuss Mountain Valley MD $MVMD, Valeo Pharma $VPH $VPHIF and Xphyto Therapeutics $XPHY $XPHYF

Posted by AGORACOM-JC at 6:36 PM on Thursday, February 11th, 2021

AGORACOM followers have given us great feedback on our hit series “Beyond The Press Release” (BTPR) in which we speak with small cap CEO’s about important press releases in greater depth and, quite frankly, in layman’s terms for investors to truly understand their significance.  

Nowhere is this more important than in the world of disruptive technologies, biotech and pharma.  Each of these industries share two distinct traits:

  • The possibility for explosive growth with disruptive new products
  • Difficulty in conveying disruptive new products that, by their nature, have never been seen before by investors.

Whereas BTPR tells these stories from the side of small cap public companies, Beyond The Expert (BTE) tells these stories from the perspective of experts on these topics – and we couldn’t think of anyone better to start off this series than Leigh Hughes.  

Leigh is a Venture Capitalist who I’ve personally watched conduct incredible due diligence and invest into many small cap companies that have generated incredible returns over 12-18 month periods.    

Leigh is so good at what he does that many global private equity funds and institutions take his call and often follow him into investments he chooses to make.  Moreover, he serves as an advisor to several small cap companies.

If you ever wanted to truly learn how to become a great small cap investor, it doesn’t get much better than this.  

Without further adieu, watch this great interview with Leigh Hughes and make sure to provide us with your feedback via comments on Twitter, YouTube or wherever you may be watching or listening.

Innocan Pharma $INNO.ca Announces Successful Production of #CBD Loaded Liposomes under Aseptic Conditions $IN.ca $AXIM $LABS $CRDL.ca $TBP.ca

Posted by AGORACOM-JC at 7:57 AM on Friday, January 22nd, 2021
Innocan-Blog
  • Announced today a successful manufacturing demonstration of liposome platform technology (“LPT“) CBD-loaded Liposomes under aseptic conditions, together with the Hebrew University of Jerusalem.
  • This is an important milestone in the production process of CBD-loaded Liposomes, as it now permits the demonstration of animal studies and, at a later date, human clinical studies ─ both of which bring the product closer to the marketplace.

Herzliya, Israel and Calgary, Alberta–(January 22, 2021) –  Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC PINK: INNPF) (the “Company” or “Innocan“), is pleased to announce today a successful manufacturing demonstration of liposome platform technology (“LPT“) CBD-loaded Liposomes under aseptic conditions, together with the Hebrew University of Jerusalem.

This is an important milestone in the production process of CBD-loaded Liposomes, as it now permits the demonstration of animal studies and, at a later date, human clinical studies ─ both of which bring the product closer to the marketplace.

This achievement supports studies on small and large animals, examining the therapeutic efficacy of Innocan’s CBD-loaded LPT in relevant diseases. These studies follow the results of previous studies that demonstrated the prolonged release of cannabidiol into the blood of mice and rats for at least three weeks after a single injection.

The previous study, led by Dr. Ahuva Cern, Senior Researcher in the laboratory of Professor Barenholz at the Hebrew University in Jerusalem, found significant amounts of CBD in the blood and muscles of mice up to 21 days after a single intramuscular injection of CBD using the LPT. The same findings were also demonstrated in rats.

Read More: https://agoracom.com/ir/InnocanPharma/forums/discussion/topics/753657-innocan-pharma-announces-successful-production-of-cbd-loaded-liposomes-under-aseptic-conditions/messages/2299445#message

Innocan Pharma $INNO.ca Successfully Completes Large Scale Production of Exosomes $IN.ca $AXIM $LABS $CRDL.ca $TBP.ca

Posted by AGORACOM-JC at 4:15 PM on Thursday, January 14th, 2021
Innocan-Blog
  • Announced the successful completion of a large-scale production of exosomes
  • Innocan’s CBD Loaded Exosome (CLX) Therapy project led by Prof. Offen demonstrates the capability of having reliable large-scale production of exosomes and is an important milestone in the CLX Therapy development process.
  • Innocan managed to perform the production of trillions of exosomes in a short period of time in a 3-dimensional bioreactor, and that may lead to economic large scale exosome production for the CLX.
  • This achievement is expected to pave the way for larger tests and studies.

Herzliya, Israel and Calgary, Alberta–(January 14, 2021) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC Pink: INNPF) (the “Company” or “Innocan“), is pleased to announce the successful completion of a large-scale production of exosomes. Innocan’s CBD Loaded Exosome (CLX) Therapy project led by Prof. Offen demonstrates the capability of having reliable large-scale production of exosomes and is an important milestone in the CLX Therapy development process. Innocan managed to perform the production of trillions of exosomes in a short period of time in a 3-dimensional bioreactor, and that may lead to economic large scale exosome production for the CLX. This achievement is expected to pave the way for larger tests and studies.

“Innocan is now one of a few public companies in the exosome’s science field. Although we are still in the development stage of the CLX platform, large scale exosome production capabilities are a significant proof of advantage and capability for Innocan, as part of the path to commercialization,” said Iris Bincovich, founder and CEO of Innocan.

Innocan Pharma together with Tel Aviv University, Prof. Offen and his team, are developing a new revolutionary cell therapy – based technology, loaded with CBD (Cannabidiol), designed to target coronavirus infected lung cells and central nervous system diseases. The CLX Therapy holds the potential to provide a highly synergistic effect of anti-inflammatory properties and help in the recovery of infected lung cells. This product is planned to act as a “guided missile” to the infected lungs, combining the cell healing properties of exosomes and the anti-inflammatory properties of CBD.

How Cannabis-Based Therapeutics Could Help Fight #COVID Inflammation – SPONSOR: Innocan Pharma $INNO.ca $IN.ca $AXIM $LABS $CRDL.ca $TBP.ca

Posted by AGORACOM-JC at 5:51 PM on Wednesday, November 4th, 2020
Innocan-Blog
  • InnoCan Pharma and Tel Aviv University are collaborating to explore the potential for CBD-loaded exosomes (minute extracellular particles that mediate intracellular communication, including via innate and adaptive immune responses)
  • The group plans to use these loaded exosomes to target and facilitate recovery of COVID-19–damaged lung cells
  • From a broader perspective, the prospects for harnessing cannabinoids for immune modulation will be more thoroughly explored in a special issue of Cannabis and Cannabinoid Research

By: Liz Scherer

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center.

Plagued by false starts, a few dashed hopes, but with perhaps a glimmer of light on the horizon, the race to find an effective treatment for COVID-19 continues. At last count, more than 300 treatments and 200 vaccines were in preclinical or clinical development (not to mention the numerous existing agents that are being evaluated for repurposing).

There is also a renewed interest in cannabinoid therapeutics — in particular, the nonpsychoactive agent cannabidiol (CBD) and the prospect of its modulating inflammatory and other disease-associated clinical indices, including SARS-CoV-2–induced viral load, hyperinflammation, the cytokine storm, and acute respiratory distress syndrome (ARDS).

Long hobbled by regulatory, political, and financial barriers, CBD’s potential ability to knock back COVID-19–related inflammation might just open doors that have been closed for years to CBD researchers.

Why CBD and Why Now?

CBD and the resulting therapeutics have been plagued by a complicated association with recreational cannabis use. It’s been just 2 years since CBD-based therapeutics moved into mainstream medicine — the US Food and Drug Administration (FDA) approved Epidiolex oral solution for the treatment of Lennox-Gastaut syndrome and Dravet syndrome, and in August, the FDA approved it for tuberous sclerosis complex.

CBD’s mechanism of action has not been fully elucidated, but on the basis of its role in immune responses — well described in research spanning more than two decades — it’s not surprising that cannabinoid researchers have thrown their hats into the COVID-19 drug development ring.

The anti-inflammatory potential of CBD is substantial and appears to be related to the fact that it shares 20 protein targets common to inflammation-related pathways, Jenny Wilkerson, PhD, research assistant professor at the University of Florida School of Pharmacy, Gainesville, Florida, explained to Medscape Medical News.

Among the various trials that are currently recruiting or are underway is one that is slated for completion this fall. CANDIDATE (Cannabidiol for COVID-19 Patients With Mild-to-Moderate COVID-19) is a randomized, controlled, double-blind study led by Brazilian researchers at the University of Sao Paulo. The study, which began recruitment this past August, enrolled 100 patients, 50 in the active treatment group (who received capsulated CBD 300 mg daily for 14 days plus pharmacologic therapy [antipyretics] and clinical measures) and 50 who received placebo.

Read Full Article: https://www.medscape.com/viewarticle/940265#vp_3

Could #Cannabis Eliminate The High-Cost And High-Stakes Of Current #Psoriasis Medicines? SPONSOR: Innocan Pharma $INNO.ca $IN.ca $AXIM $LABS $CRDL.ca $TBP.ca

Posted by AGORACOM-JC at 6:04 PM on Thursday, October 29th, 2020

SPONSOR: Innocan Pharma Corporation (INNO:CSE) (IP4:FSE) Innocan has 3 fully operating divisions to address the market for Cannabis products.  As a Cannabis investor, why limit yourself to a Company with just one specialty, when Innocan offers you exposure to both the exploding world of cannabis pharma, as well as, a portfolio of patent-pending and launch ready consumer health products. In addition, the company filed an international patent application for a novel cannabis-based psoriasis treatment. This patent application makes claim of a topical pharmaceutical composition used to treat the symptoms of itching and inflammation associated with psoriasis.

  • “The global psoriasis drugs market is forecast to reach USD 39.00 Billion by 2027.
Innocan-Blog

Could Cannabis Eliminate The High-Cost And High-Stakes Of Current Psoriasis Medicines?

  • Often triggered by stress, new studies are showing that psoriasis can be better managed by diet, oral health, and even cannabidiol.
  • The National Psoriasis Foundation shared information on a study from the Journal of Dermatological Science showcasing that, “CBD may offer therapeutic value for psoriasis by slowing the overgrowth of certain skin cells.” 
  • A 2016 study published in the journal Current Clinical Pharmacology found similar results, citing that cannabinoids may be a positive addition to treatment for psoriasis.
  • Even better, a 2018 study did a sweeping review of prior research on cannabis’ role within dermatology and found, “cannabinoids have shown some initial promise as a therapy for a variety of skin diseases.” Their only concern was a lack of research in clinical trials, due to the Schedule 1 classification of the drug.  

By: Kate-Madonna Hindes

The National Psoriasis Foundation states that upwards of 8 million people have the auto-immune skin disorder. Often accompanied by arthritis, psoriasis not only causes scaling of the skin, but complications to fingernails as well. 

Affecting everyone from children to adults, psoriasis can lead to anxiety and depression, as individuals with the skin disorder are often afraid of being ridiculed. Usually treated with Humira and Enbrel, psoriasis comes with a shocking price tag and complications that are often difficult to ignore. 

A 2014 study published in the journal Drugs in Context found that Humira had a price tag upwards of $39,000, while Enbrel’s annual cost was around $46,000. Stelara, the most expensive drug, was found to cost over $53,000. As TNF blockers, while medications like Humira help against psoriasis, they can lower the body’s ability to fight infections and cause serious side effects.

Even more interesting, a September 2019 study in London found that, “A number of medications commonly prescribed by rheumatologists may interact with cannabidiol oil” (CBD oil). The most affected medicines appear to be corticosteroids (including hydrocortisone and prednisolone) since CBD, “is a potent inhibitor of CYP3A.” Put plainly, CBD may block the effects of the other medicine.

Image Credit: Aleksandr_Kravtsov | Getty Images via The Fresh Toast

Can CBD alone help psoriasis? 

Often triggered by stress, new studies are showing that psoriasis can be better managed by diet, oral health, and even cannabidiol. The National Psoriasis Foundation shared information on a study from the Journal of Dermatological Science showcasing that, “CBD may offer therapeutic value for psoriasis by slowing the overgrowth of certain skin cells.” 

A 2016 study published in the journal Current Clinical Pharmacology found similar results, citing that cannabinoids may be a positive addition to treatment for psoriasis. Even better, a 2018 study did a sweeping review of prior research on cannabis’ role within dermatology and found, “cannabinoids have shown some initial promise as a therapy for a variety of skin diseases.” Their only concern was a lack of research in clinical trials, due to the Schedule 1 classification of the drug.  

While CBD and cannabis offer pain relief and psoriasis is often accompanied by rheumatoid arthritis, each individual must discuss the addition of any new medicine (including CBD and cannabis) with their care team. With new clinical trials for cannabinoids and psoriasis recruiting even now, promising cures may be on the horizon.

Source: https://www.greenentrepreneur.com/article/358275

Innocan Pharma $INNO.ca Announces the Publication of Two Studies Supporting Its CLX Therapy for COVID-19 Infected Lung Cells $IN.ca $AXIM $LABS $CRDL.ca $TBP.ca

Posted by AGORACOM-JC at 7:35 AM on Friday, October 23rd, 2020
Innocan-Blog
  • Announced the recent publication of two scientific articles supporting Innocan’s approach of using CBD-Loaded Exosomes (CLX) for the treatment of COVID-19
  • The first paper entitled, “Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients” published in the Journal of Stem Cell Research & Therapy on October 15, 2020
  • study demonstrated that exosomes have the ability to enhance alveolar fluid clearance and promote epithelial and endothelial recovery through secretion of protective factors
  • The second paper entitled, “Cannabidiol (CBD) modulation of apelin in acute respiratory distress syndrome” published in the Journal of Cellular and Molecular Medicine on October 15, 2020
  • Demonstrated that the non-psychoactive reagent in cannabis (CBD) can significantly reduce the lung damage induced by cytokine storms

Herzliya, Israel and Calgary, Alberta–(October 23, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan“), is pleased to announce the recent publication of two scientific articles supporting Innocan’s approach of using CBD-Loaded Exosomes (CLX) for the treatment of COVID-19. The first paper entitled, “Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients” published in the Journal of Stem Cell Research & Therapy on October 15, 2020 outlined that mesenchymal stem cells (MSCs) and their exosomes have potential therapeutic functions in the handling of COVID-19. Specifically, the study demonstrated that exosomes have the ability to enhance alveolar fluid clearance and promote epithelial and endothelial recovery through secretion of protective factors.

The second paper entitled, “Cannabidiol (CBD) modulation of apelin in acute respiratory distress syndrome” published in the Journal of Cellular and Molecular Medicine on October 15, 2020, demonstrated that the non-psychoactive reagent in cannabis (CBD) can significantly reduce the lung damage induced by cytokine storms (which is a physiological reaction in humans and other animals in which the innate immune system causes an uncontrolled and excessive release of pro-inflammatory signaling molecules called cytokines) caused by COVID-19.

Innocan Israel, a wholly owned subsidiary of the Company, together with Tel Aviv University Prof. Daniel Offen and his team, are developing a revolutionary combined therapy using MSC-driven Exosome-based loaded with CBD. The new combination is designed to target COVID-19 and neurodegenerative diseases.

Through their potential synergistic anti-inflammatory effect, CBD-Loaded Exosomes hold the potential of helping the body fight against the COVID-19 virus’s direct damage and its cytokine storm. This product is planned to act as a “guided missile” to the infected tissues, as the Exosomes migrate to Inflamed zones that are carrying CBD.

Prof. Offen added: “The recent publications which support our unique approach is exciting. The potential synergistic effect of CBD and Exosomes is of great potential for COVID-19 and other diseases known for local inflammation that causes destruction. We are doing our best efforts to accelerate the development and to potentially offer a new approach for the COVID-19 treatment”.

About Innocan

Innocan Israel is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing CBD. Innocan Israel and Ramot at Tel Aviv University, are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the COVID-19 Coronavirus using CBD. CBD-Loaded Exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of The Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. Innocan Israel plans, together with Professor Berenholtz Head of the Laboratory of Membrane and Liposome Research of The Hebrew University of Jerusalem, to test the liposome platform on several potential indications. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for the relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan Israel each have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

Innocan Pharma Corporation
Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable

REMINDER: Innocan Pharma $INNO.ca to Provide Corporate Update via Livestream Video Today at 10am EST $IN.ca $AXIM $LABS $CRDL.ca $TBP.ca

Posted by AGORACOM-JC at 8:25 AM on Wednesday, October 14th, 2020
Innocan-Blog

The company will provide a corporate update to the investment community and shareholders through a YouTube livestream video on today at 10:00am EST.

The update will include a corporate presentation by Innocan’s CEO Iris Bincovich describing the key research milestones achieved by the company to date, and a scientific review by Innocan’s Scientific Advisor Professor Daniel Offen.

The YouTube livestream video will be available through livestream.innocanpharma.com

Hub On AGORACOM / Read Recent Release…

Innocan Achieves Major Milestone in Developing Its Unique CBD-Loaded Liposome Platform Technology for Injectable CBD

  • Study on mice demonstrated a prolonged release of Cannabidiol into the blood for at least three weeks after one administration
  • Conducted based on Innocan’s licensed CBD loaded liposome platform technology for injectable CBD
  • Conducted on over 35 mice and found significant amounts of CBD in the mice’s blood 21 days after they were injected with a single injection of liposomal CBD using Innocan’s CBD loaded LPT
  • Results are substantial when comparing the oral or smoking administration of CBD, in which CBD was found in the blood of mice only for a period of up to 36 hours after one administration
  • Results open the door for future experiments to prove the lack of toxicity and beneficial therapeutic efficacy of the formulations.